3468-18-6

Basic information

• Product Name: 4-AMINOMETHYLINDOLE
• Synonyms: 1H-INDOLE-4-METHANAMINE;(1H-INDOL-4-YLMETHYL)AMINE;4-AMINOMETHYLINDOLE;INDOLE-4-METHYLAMINE;CHEMBRDG-BB 4003293;C-(1H-INDOL-4-YL)-METHYLAMINE;NSC 131886;(1H-Indol-4-ymetyl)amine
• CAS NO: 3468-18-6
• Molecular Formula: C₉H₁₀N₂
• Molecular Weight: 146.19
• Product Categories: pharmacetical
• Mol File: 3468-18-6.mol
• Article Data: 8

Chemical Properties

• Melting Point: 132℃
• Boiling Point: 335.6 °C at 760 mmHg
• Flash Point: 183.3 °C
• Appearance: crystalline solid
• Density: 1.199
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• Solubility: Soluble in ethanol, dimethyl sulfoxide and dimethyl formamide.
• PKA: 17.21±0.30(Predicted)
• Water Solubility: DMSO:PBS ( 7.2) (1:1), also sol. in EtOH,DMSO&DMF
• CAS DataBase Reference: 4-AMINOMETHYLINDOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-AMINOMETHYLINDOLE(3468-18-6)
• EPA Substance Registry System: 4-AMINOMETHYLINDOLE(3468-18-6)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 36/37/38-41-37/38-22
• Safety Statements: 26-36/37/39
• HazardClass: IRRITANT
• Hazardous Substances Data: 3468-18-6(Hazardous Substances Data)

Usage

Description

4-Aminomethylindole is a synthetic intermediate that serves as a crucial component in pharmaceutical synthesis, playing a significant role in the development of various medicinal compounds.

Uses

Used in Pharmaceutical Industry:
4-Aminomethylindole is used as a research intermediate for the preparation of dopamine receptor antagonists, which are essential in the treatment of various neurological and psychiatric disorders. Its role in the synthesis of these antagonists makes it a valuable asset in the development of effective medications for such conditions.
Used in Neurological Research:
As a reactant for the preparation of high-affinity ligands to the α2δ subunit of voltage-gated calcium channels, 4-Aminomethylindole contributes to the advancement of research in the field of neurology. These ligands are instrumental in studying the function and modulation of voltage-gated calcium channels, which are implicated in numerous neurological processes and diseases.

Upstream product

• 1074-86-8 4-formyl indole 
• 16136-52-0 4-cyanoindole 
• 144-55-8 sodium hydrogencarbonate 

Downstream Products

• 53462-74-1 3-thiophen-2-yl-1,3,4,5-tetrahydro-pyrrolo[4,3,2-de]isoquinoline 
• 1217181-05-9 2-(indol-4-ylmethyl)-3,4-dihydroisoquinolinium bromide 
• 1373945-72-2 C₂₁H₂₁F₂N₃O 
• 1373945-74-4 C₂₀H₁₉F₂N₃O 
• 1373945-62-0 C₂₃H₁₇F₂N₃O 
• 1373945-64-2 C₂₃H₁₆BrF₂N₃O 
• 1373945-66-4 C₂₂H₁₆F₂N₄O 
• 1373945-68-6 C₂₀H₁₉F₂N₃O 
• 1373945-70-0 C₂₃H₂₅F₂N₃O 
• 1373945-76-6 C₂₃H₂₃F₂N₃O 
• 1447525-13-4 N-((1H-indol-4-yl)methyl)-N-(2-(tert-butylamino)-2-oxo-1-phenylethyl)but-2-ynamide 

Relevant articles and documents

Au(I)-Catalyzed Pictet-Spengler Reactions All around the Indole Ring

Au(I) complexes catalyze iso-Pictet-Spengler reactions. Ethylamine or methylamine chains were introduced at C2, C4, or the nitrogen atom of the indole ring, and the corresponding substrates were reacted in the presence of aldehydes and catalytic amounts of Au(I) complexes, leading to a variety of polycyclic scaffolds. Selectivity could be achieved in the course of a double iso-Pictet-Spengler reaction involving two successive aldehydes, leading to highly complex molecules.

4-Indolyl-N-hydroxyphenylacrylamides as potent HDAC class I and IIB inhibitors in?vitro and in?vivo

A series of 4,5-indolyl-N-hydroxyphenylacrylamides, as HDAC inhibitors, has been synthesized and evaluated in?vitro and in?vivo. 4-Indolyl compounds 13 and 17 functions as potent inhibitors of HDAC1 (IC50 1.28?nM and 1.34?nM) and HDAC 2 (ICsub

THIAZOLE AND THIOPHENE COMPOUNDS

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of inflammatory diseases and disorders such as, for example, asthma and COPD